Arrowstreet Capital Limited Partnership Purchases Shares of 56,000 Agilent Technologies, Inc. (A)

Arrowstreet Capital Limited Partnership purchased a new stake in Agilent Technologies, Inc. (NYSE:A) in the second quarter, according to its most recent filing with the SEC. The fund purchased 56,000 shares of the medical research company’s stock, valued at approximately $3,321,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisor Group Inc. increased its holdings in shares of Agilent Technologies by 0.3% in the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Agilent Technologies by 0.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock worth $276,000 after buying an additional 35 shares during the last quarter. Veritable L.P. grew its stake in Agilent Technologies by 0.4% during the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock worth $646,000 after buying an additional 40 shares during the last quarter. Park National Corp OH grew its stake in Agilent Technologies by 1.1% during the 2nd quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock worth $242,000 after buying an additional 43 shares during the last quarter. Finally, Trust Co. of Vermont grew its stake in Agilent Technologies by 1.8% during the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after buying an additional 50 shares during the last quarter.

A number of brokerages recently commented on A. Deutsche Bank AG set a $68.00 price objective on Agilent Technologies and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Wells Fargo & Company upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. BidaskClub upgraded Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. J P Morgan Chase & Co restated an “overweight” rating and set a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, August 16th. Finally, Bank of America Corporation upped their price objective on Agilent Technologies from $66.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 16th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $65.12.

In other news, CFO Didier Hirsch sold 15,555 shares of Agilent Technologies stock in a transaction on Friday, September 15th. The stock was sold at an average price of $66.00, for a total value of $1,026,630.00. Following the completion of the sale, the chief financial officer now directly owns 178,557 shares of the company’s stock, valued at approximately $11,784,762. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dominique Grau sold 13,007 shares of Agilent Technologies stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $62.00, for a total value of $806,434.00. Following the completion of the sale, the insider now directly owns 60,098 shares of the company’s stock, valued at $3,726,076. The disclosure for this sale can be found here. Insiders sold a total of 165,720 shares of company stock valued at $10,488,739 over the last three months.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/10/18/arrowstreet-capital-limited-partnership-purchases-shares-of-56000-agilent-technologies-inc-a.html.

Shares of Agilent Technologies, Inc. (A) opened at 66.12 on Wednesday. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $67.82. The stock has a 50 day moving average price of $65.36 and a 200 day moving average price of $60.01. The firm has a market cap of $21.27 billion, a price-to-earnings ratio of 47.23 and a beta of 1.30.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. On average, equities research analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 25th. Stockholders of record on Tuesday, October 3rd will be paid a $0.132 dividend.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Advisor Group Inc. increased its holdings in shares of Agilent Technologies by 0.3% in the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Agilent Technologies by 0.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock worth $276,000 after buying an additional 35 shares during the last quarter. Veritable L.P. grew its stake in Agilent Technologies by 0.4% during the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock worth $646,000 after buying an additional 40 shares during the last quarter. Park National Corp OH grew its stake in Agilent Technologies by 1.1% during the 2nd quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock worth $242,000 after buying an additional 43 shares during the last quarter. Finally, Trust Co. of Vermont grew its stake in Agilent Technologies by 1.8% during the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock worth $166,000 after buying an additional 50 shares during the last quarter.

A number of brokerages recently commented on A. Deutsche Bank AG set a $68.00 price objective on Agilent Technologies and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Wells Fargo & Company upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. BidaskClub upgraded Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. J P Morgan Chase & Co restated an “overweight” rating and set a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, August 16th. Finally, Bank of America Corporation upped their price objective on Agilent Technologies from $66.00 to $68.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 16th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $65.12.

In other news, CFO Didier Hirsch sold 15,555 shares of Agilent Technologies stock in a transaction on Friday, September 15th. The stock was sold at an average price of $66.00, for a total value of $1,026,630.00. Following the completion of the sale, the chief financial officer now directly owns 178,557 shares of the company’s stock, valued at approximately $11,784,762. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dominique Grau sold 13,007 shares of Agilent Technologies stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $62.00, for a total value of $806,434.00. Following the completion of the sale, the insider now directly owns 60,098 shares of the company’s stock, valued at $3,726,076. The disclosure for this sale can be found here. Insiders sold a total of 165,720 shares of company stock valued at $10,488,739 over the last three months.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://ledgergazette.com/2017/10/18/arrowstreet-capital-limited-partnership-purchases-shares-of-56000-agilent-technologies-inc-a.html.

Shares of Agilent Technologies, Inc. (A) opened at 66.12 on Wednesday. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $67.82. The stock has a 50 day moving average price of $65.36 and a 200 day moving average price of $60.01. The firm has a market cap of $21.27 billion, a price-to-earnings ratio of 47.23 and a beta of 1.30.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. On average, equities research analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 25th. Stockholders of record on Tuesday, October 3rd will be paid a $0.132 dividend. The ex-dividend date is Monday, October 2nd. This represents a $0.53 annualized dividend and a dividend yield of 0.80%. Agilent Technologies’s dividend payout ratio (DPR) is currently 27.32%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply